| Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. R Bruno, D Hille, A Riva, N Vivier, WW ten Bokkel Huinnink, ... Journal of clinical oncology 16 (1), 187-196, 1998 | 494 | 1998 |
| Clinical pharmacokinetics of bevacizumab in patients with solid tumors JF Lu, R Bruno, S Eppler, W Novotny, B Lum, J Gaudreault Cancer chemotherapy and pharmacology 62, 779-786, 2008 | 396 | 2008 |
| Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics L Claret, P Girard, PM Hoff, E Van Cutsem, KP Zuideveld, K Jorga, ... Journal of Clinical Oncology 27 (25), 4103-4108, 2009 | 338 | 2009 |
| A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation R Bruno, N Vivier, JC Vergniol, SL De Phillips, G Montay, LB Sheiner Journal of pharmacokinetics and biopharmaceutics 24, 153-172, 1996 | 337 | 1996 |
| Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion JM Extra, F Rousseau, R Bruno, M Clavel, NL Bail, M Marty Cancer research 53 (5), 1037-1042, 1993 | 330 | 1993 |
| Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer R Bruno, CB Washington, JF Lu, G Lieberman, L Banken, P Klein Cancer chemotherapy and pharmacology 56, 361-369, 2005 | 292 | 2005 |
| Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer JF Lu, SM Eppler, J Wolf, M Hamilton, A Rakhit, R Bruno, BL Lum Clinical Pharmacology & Therapeutics 80 (2), 136-145, 2006 | 257 | 2006 |
| The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance JA Hirth, PB Watkins, M Strawderman, A Schott, R Bruno, LH Baker Clinical cancer research 6 (4), 1255-1258, 2000 | 248 | 2000 |
| Population pharmacokinetics of rituximab (anti‐CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial CM Ng, R Bruno, D Combs, B Davies The Journal of Clinical Pharmacology 45 (7), 792-801, 2005 | 228 | 2005 |
| Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. CA Hudis, AD Seidman, JP Crown, C Balmaceda, R Freilich, TA Gilewski, ... Journal of clinical oncology 14 (1), 58-65, 1996 | 180 | 1996 |
| Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer L Claret, M Gupta, K Han, A Joshi, N Sarapa, J He, B Powell, R Bruno Journal of Clinical Oncology 31 (17), 2110-2114, 2013 | 159 | 2013 |
| Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function I Mahé, M Aghassarian, L Drouet, K Lacut, JJ Heilmann, D Mottier, ... Thrombosis and haemostasis 97 (04), 581-586, 2007 | 148 | 2007 |
| Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel R Bruno, N Vivier, C Veyrat-Follet, G Montay, GR Rhodes Investigational new drugs 19, 163-169, 2001 | 144 | 2001 |
| Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma M Stroh, H Winter, M Marchand, L Claret, S Eppler, J Ruppel, O Abidoye, ... Clinical Pharmacology & Therapeutics 102 (2), 305-312, 2017 | 137 | 2017 |
| Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics S Retout, F Mentré, R Bruno Statistics in medicine 21 (18), 2623-2639, 2002 | 122 | 2002 |
| Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method JC Vergniol, R Bruno, G Montay, A Frydman Journal of Chromatography B: Biomedical Sciences and Applications 582 (1-2 …, 1992 | 122 | 1992 |
| Fixed dosing of HER antibodies DE Allison, R Bruno, JF Lu, CM Ng US Patent 7,449,184, 2008 | 120* | 2008 |
| α-1-Acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel R Bruno, R Olivares, J Berille, P Chaikin, N Vivier, L Hammershaimb, ... Clinical cancer research 9 (3), 1077-1082, 2003 | 115 | 2003 |
| Pharmacokinetics and metabolism of Taxotere (docetaxel). R Bruno, GJ Sanderink Cancer surveys 17, 305-313, 1993 | 111 | 1993 |
| Pharmacokinetics of nicorandil AM Frydman, P Chapelle, H Diekmann, R Bruno, JJ Thebault, J Bouthier, ... The American journal of cardiology 63 (21), J25-J33, 1989 | 106 | 1989 |
Francois MercierF. Hoffmann-La RocheVerified email at roche.com
